GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

GSK said Wednes­day that it is pay­ing up to $2.2 bil­lion to re­solve 93% of its US state-based li­a­bil­i­ty cas­es re­lat­ed to its heart­burn med­i­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA